

## References

### S-131

1. Duelund-Jakobsen J, Worsoe J, Lundby L, et al. Management of patients with faecal incontinence. *Therap Adv Gastroenterol*. 2016;9(1):86–97.
2. Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. *World J Gastrointest Pharmacol Ther*. 2016;7(2):294–305.
3. Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: A randomized clinical trial. *JAMA*. 2016; 316(13):1366-1374.
4. National Institute for Health and Care Excellence (NICE). Faecal incontinence in adults: management [CG49]. 2007.
5. Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. *Neurourol Urodyn*. 2016;35(2):246-51.
6. Pilkington SA, Emmett C, Knowles CH, et al. Surgery for constipation: Systematic review and practice recommendations: Results V: Sacral nerve stimulation. *Colorectal Dis*. 2017;19(3):92-100.
7. Hayes, Inc. Hayes Health Technology Assessment. *Staged approach to sacral nerve stimulation for treatment of fecal incontinence*. Lansdale, PA: Hayes, Inc.; 12/29/2018
8. Zerbib F, Siproudhis L, Lehur PA, et al. Randomized clinical trial of sacral nerve stimulation for refractory constipation. *Br J Surg*. 2017;104(3):205-213.
9. Hayes, Inc. Hayes Health Technology Assessment. *Axonics (axonics neuromodulation technologies inc.) versus interstim (medtronic) sacral neuromodulation systems for urinary or fecal incontinence*. Lansdale, PA. Hayes, Inc.; 10/16/2020.
10. Kraus SR, Shiozawa A, Szabo SM, et al. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. *Neurourol Urodyn*. 2020;39(8):2206-2222.
11. Hayes, Inc. Hayes Health Technology Assessment. *Axonics sacral neuromodulation (axonics neuromodulation technologies) for the management of urinary dysfunction*. Lansdale, PA. Hayes, Inc.; 09/28/2020. Accessed on 04/07/2021.
12. Hayes, Inc. Hayes Health Technology Assessment. *Percutaneous tibial nerve stimulation for the treatment of symptomatic neurogenic lower urinary tract dysfunction*. Lansdale, PA. Hayes, Inc.; 07/31/2020.

13. Diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adults:  
an AUA/SUFU Guideline (2019).  
[https://www.auanet.org/guidelines/overactive-bladder-\(oab\)-guideline](https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline).  
Accessed June 03, 2021.